All down ACTC AAPL Geron

Bad day, AAPL down big closing at $576.80, ACTC down under 7 cents, and Geron down 7 cents at $1.32......., ............................................................... ............................................................................................................................................................................. Nothing good will happen till after the election and the fiscal cliff is fixed......... .................................................................................................................................................................................................................................................................... Good luck in this rigged casino,

Geron up, ACTC up and AAPL up

Geron was up 6 cents on very light volume only 560,143 shares. The three month avg is 1.6 million shares. Remember Chip said in a few days Geron will file a SEC 10-K report on the BioTime deal. BioTime was down 14 cents to $3.67 just a week ago it was over $4. The volume was 2xs the normal. Based on BioTime's price drop and volume I'm thinking Geron may take the deal, I hope GE makes a offer. Time was tell. ..................................................................................................................................................................................................................................................................... ACTC closed at 7 cents on avg. volume. Still waiting on results of Phase 1/2 trials should be in 3 to 6 months. .................................................................................................................................................................................................................................................................... AAPL up just a little to close at $596.54. Hoping people buy 10 million mini Ipods for the holidays......................................................................... ..............................................................................................................................................................................Good luck in this rigged casino,

Geron Earning Call

Well I read the earnings call and learned next to nothing. Upset about no infor on the stell cell deal. Chip did say in a few days will file a SEC 10-K about the BioTime deal. Chip said reports of Phase 2 trials will be coming in Dec. Again this will make or break Geron. I have no good or bad feeling about up coming reports. Good luck in this rigged casino,

ACTC gets OK for 2nd Patient Cohort in Trials for Dry AMD

Advanced Cell Technology, Inc. ("ACT"; OTCBB: ACTC), a leader in the field of regenerative medicine, announced today that the Data and Safety Monitoring Board (DSMB), an independent group of medical experts closely monitoring the Company's three ongoing clinical trials, has authorized the Company to move forward with enrollment and treatment of two additional patients with dry age-related macular degeneration (dry AMD). ACT will screen and enroll the second and third patients of the three-patient second cohort in the trial. Per trial protocol, each patient will be injected with 100,000 human embryonic stem cell (hESC)-derived retinal pigment epithelial (RPE) cells. "Dry AMD represents one of the largest unmet medical needs in the world, and we are thrilled to be making steady progress in our clinical trial for this condition," commented Gary Rabin, ACT's chairman and CEO. "We are well on our way to the halfway point of all three of our clinical trials. We also recently secured DSMB approval to complete the second cohort of our two trials for Stargardt's Macular Dystrophy." ACT is conducting three clinical trials in the U.S. and Europe using hESC-derived RPE cells to treat forms of macular degeneration, dry AMD and Stargardt's Macular Dystrophy (SMD). Each trial will enroll a total of 12 patients, with cohorts of three patients each in an ascending dosage format, from 50,000 to 200,000 hESC-derived RPE cells. These trials are prospective, open-label studies, designed to determine the safety and tolerability of hESC-derived RPE cells following sub-retinal transplantation into patients with dry AMD or SMD at 12 months, the study's primary endpoint. "This authorization to treat the next two patients in the second, higher-dosage cohort of our trial for dry AMD represents a notable milestone for our clinical programs," commented Robert Lanza, M.D., ACT's chief scientific officer. "We look forward to treating these two patients and moving on to the third cohort in good time." Good news trials moving forward. Good luck in this rigged casino,

Working till I drop over dead thanks AAPL

AAPL missed earnings est. but just a little. I'll sell the three calls one at a time, one in Dec, Jan and Feb, hoping I can cut the loss to 40% which is still a big loss. AAPL closed down $5.54 at $604 alot of volume 36.7 million shares. The three month avg. volume is 16.7 million shares. ................................................... .............................................................................................................................................................................. Geron up 3 cents at $1.30 volume a little better at 1.2 million shares. Dec, Geron will tell us how the last 4 Phase two trials are going. If there is any run up I'm sell 5 thousand shares. Geron as been batting zero I can't lose more money on this company. .............................................................................................................................................................................. ACTC down a little at 0.0701 on 4.4 million shares. Need news or we go lower........... .............................................................................................................................................................................. Good luck in this rigged casino,

AAPPL, ACTC and Geron all up

AAPL was up $3.47 to close at $616.83 on 19.8 million shares. Thursday is the make or break day for my calls. Need blow out earnings and a $50+ run up....................... .....................................................................................................................................................................................................................................................................ACTC up a little at 0.0710. Only 3.9 million shares the three month avg. volume is 5.7 million shares. With no news we go lower. May buy a little under 7 cents............... ............................................................................................................................................................................................................................................................................................................................................................ Geron no news on the deal, I'm betting Chip will tell all Oct 30th at 4:30PM it will be webcast, earninngs call. Geron closed at $1.34 up 2 cents volume was only 405,164 shares. There's no interest in this company. Need good news on the last 4 Phase two trials. If no good news we go under $1.....................................................................................May add BTX to my holdings but only 100 shares................................... .......................................................................................Good luck in this rigged casino,

AAPL down big, ACTC and Geron down

AAPL's iPod mini looks great but the $329 price may be to much, so the market thinks. I'm thinking they will sell 10 million+. Down $20.67 to close at $613.36, volume was 25.1 million shares. The three month avg. volume 16.3 million shares. ..................................................................................................................................................................................................................................................................................ACTC down a little at 0.0702, holding 7 cents but not for long without good news. ..................................................................................................................................................................................................................................................................................Geron down a little at $1.32 on 768,621 shares. No word on the BioTime deal..................................................................................................................................................................................................................................................................Good luck in this rigged casino,